With India's "regulatory turf-war" over, all eyes turn to the US
This article was originally published in Clinica
The "turf-war" between India's ministries of health and family welfare (MoHFW) and science and technology (DST) - over whose medtech regulatory bill gets made into law - is all but over.
You may also be interested in...
GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.
Lab testing for COVID-19 has risen to a new high of 314,000 tests per week in Germany, where the concerns are perhaps less about test availability than staff numbers to oversee the testing protocols.
A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.